Leading businesses, research labs and universities choose us as their healthcare intelligence partners.
Learn how these leading companies have integrated Pumas® Products as an essential component of their workflow
Customer Testimonials
PumasAI worked with us with incredible flexibility and agility despite tight timelines and sometimes the need for re-work or additional evaluation, as often is the case with data driven exercises.
BMS
We are impressed by the quality and breadth of the experience of PumasAI scientists in collaborating with us on modeling and simulation projects across our pipeline spanning investigational therapeutics and vaccines at various stages of clinical development.
Moderna Therapeutics
...The collaboration spans across the continuum of the drug development cycle, Clinical Development, Clinical Pharmacology, Pharmacometrics, Regulatory, and Strategy. One of these collaborations for a cardio-renal asset, has resulted in a precedent-setting registration pathway where the conventional approach was not viable...
Otsuka Pharmaceutical Companies (U.S.)
We have a high priority oncology drug development portfolio at our company. PumasAI provided us with high quality MIDD work product which supported regulatory submissions in a timely manner. It is a pleasure to work with PumasAI scientists, and we highly recommend them!
Arcus Biosciences
PumasAI is a valued partner and works very hard to help us achieve our goal. I would recommend PumasAI highly.
Relay Therapeutics
PumasAI developed a revolutionary platform for model based drug development which utilizes the powerful Julia programming language. Data integration, model specification, and post-processing are easy and convenient. PumasAI product is a breath of fresh air and a real winner.
Sr. Pharmacokineticist, P&G Pharmaceuticals
Recently we worked with Dr Gobburu and his team on applying Model-informed Drug Development (MIDD) approach to support the development of one of our key assets. This work led to a successful meeting with the FDA and shortening the drug development program tremendously.
Sr. Vice President, Proprietary Products, Dr. Reddy's Laboratories Limited
We have been using Pumas software for our pharmacometric needs to support our development decisions and regulatory submissions. Pumas software has surpassed our expectations on its accuracy and ease of use.
Director, Head of Clinical Pharmacology and Pharmacometrics, Moderna Therapeutics, Inc
The professionalism, collegiality, and unparalleled drug development acumen are some of the biggest differentiators that we see with the PumasAI, Inc.. We are already working on an MIDD meeting for another product with PumasAI, Inc. and look forward to continuing our collaborations.
VP Head of Early Phase Development and Translational Medicine at Otsuka Pharmaceutical Companies (U.S.)
The Center for Translational Medicine, University of Maryland, Baltimore, was instrumental in helping us obtain approval from the FDA. The trial involves individualization of patient doses using Pumas software based on non-compartmental analysis and modeling. We look forward to working with Drs. Long-Boyle and Gobburu on this important project.
Stem Cell Transplantation Program, Department of Pediatric Oncology, Dana-Farber Cancer Institute Division of Hematology/oncology, Boston Children’s Hospital
The CTM’s Dr. Allison Dunn and Dr. Gobburu have provided timely and high quality scientific analyses and regulatory input to our team. Their analyses have helped us make key internal decisions, and also submitted to multiple regulatory agencies across the world successfully. All the modeling and simulation analyses were conducted using Pumas software.
VP Research and Development at Newamsterdam Pharma & Founder Diomedea Medical Bv
PumasAI worked with us with incredible flexibility and agility despite tight timelines and sometimes the need for re-work or additional evaluation, as often is the case with data driven exercises.
BMS
